Daniel Thwaites

Daniel Thwaites

Auto-generated profile, based on publicly available information

Daniel Thwaites

School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
DLDylan Lawless
Dylan Lawless
CGChristoph B. Geier
Christoph B. Geier
JFJocelyn R. Farmer
Jocelyn R. Farmer
HAHana Lango Allen
Hana Lango Allen
DTDaniel Thwaites
Daniel Thwaites
SSSinisa Savic
Sinisa Savic

21 February 2019 in Blood
Verified
Journal Article
Closed access
PDF file
DTDaniel T. Thwaites
Daniel T. Thwaites
CCClive Carter
Clive Carter
DLDylan Lawless
Dylan Lawless
SSSinisa Savic
Sinisa Savic
JBJoan Boyes
Joan Boyes
The Recombination Activating Genes, RAG1 and RAG2, are essential for V(D)J recombination and adaptive immunity. Mutations in these genes often cause immunodeficiency, the severity of which reflects the importance of the altered residue or residues during recombination. Here, we describe a novel RAG1 mutation that causes immunodeficiency in an unexpected way: The mutated protein severely disrupts binding of the accessory protein, HMGB1. Although HMGB1 enhances RAG cutting in vitro, its role in vivo was controversial. We show here that reduced HMGB1 binding by the mutant protein dramatically reduces RAG cutting in vitro and almost completely eliminates recombination in vivo. The RAG1 mutation, R401W, places a bulky tryptophan opposite the binding site for HMG Box A at both 12- and 23-spacer recombination signal sequences, disrupting stable binding of HMGB1. Replacement of R401W with leucine and then lysine progressively restores HMGB1 binding, correlating with increased RAG cutting and recombination in vivo. We show further that knockdown of HMGB1 significantly reduces recombination by wild-type RAG1, whereas its re-addition restores recombination with wild-type, but not the mutant, RAG1 protein. Together, these data provide compelling evidence that HMGB1 plays a critical role during V(D)J recombination in vivo.

16 April 2019 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
MDMayra B. Dorna
Mayra B. Dorna
PBPamela F. A. Barbosa
Pamela F. A. Barbosa
ARAndréia Rangel-Santos
Andréia Rangel-Santos
KCKrisztian Csomos
Krisztian Csomos
BUBoglarka Ujhazi
Boglarka Ujhazi
JWJolan E Walter
Jolan E Walter
Proteins expressed by recombination activating genes 1 and 2 (RAG1/2) are essential in the process of V(D)J recombination that leads to generation of the T and B cell repertoires. Clinical and immunological phenotypes of patients with RAG deficiencies correlate well to the degree of impaired RAG activity and this has been expanding to variants of combined immunodeficiency (CID) or even milder antibody deficiency syndromes. Pathogenic variants that severely impair recombinase activity of RAG1/2 determine a severe combined immunodeficiency (SCID) phenotype, whereas hypomorphic variants result in leaky (partial) SCID and other immunodeficiencies. We report a patient with novel pathogenic compound heterozygous RAG2 variants that result in a CID phenotype with two distinctive characteristics: late-onset progressive hypogammaglobulinemia and highly elevated B cell count. In addition, the patient had early onset of infections, T cell lymphopenia and expansion of lymphocytes after exposure to herpes family viruses. This case highlights the importance of considering pathogenic RAG variants among patients with preserved B cell count and CID phenotype.

5 February 2026 in Blood Vessels, Thrombosis & Hemostasis
Verified
Journal Article
Open access
ELEmma Lund
Emma Lund
ASAlexander Silvester
Alexander Silvester
DTDaniel Thwaites
Daniel Thwaites
YBYasmin Bennour
Yasmin Bennour
MMMatthew McKechnie
Matthew McKechnie
CCChristopher Cooper
Christopher Cooper
• Single‑donor human whole blood and blood fraction models of blood vessels were established for early phase drug safety assessments. • Models were applied in both 2D plate-based and 3D vascular structure formats for tailoring of data output to research requirements.

1 August 2004 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
DTDaniel Thwaites
Daniel Thwaites
SMShawn McCann
Shawn McCann
PBPeter Broderick
Peter Broderick
Continuous parenteral hydromorphone is used to treat pain in palliative care. Case reports have suggested that neuroexcitatory symptoms, such as agitation, myoclonic activity, and even seizures may occur during administration. However, little information exists on the incidence of these side effects or their relationship to the dose or duration of parenteral hydromorphone. A retrospective chart review was performed on 48 terminally ill hospice patients who received continuous parenteral hydromorphone for pain control. Chart reviews were conducted searching for three neuroexcitatory symptoms: agitation, myoclonus, and seizures; the incidence and relationship of these symptoms were statistically compared to the maximal dose and number of days on continuous parenteral hydromorphone. We found that agitation, myoclonus, and seizures were not associated with the patients gender, age, or diagnosis but found that agitation was associated (p < 0.01) in patients with known metastatic disease. Agitation, myoclonus, and seizures were independently associated with the maximal dose (p < 0.05, p , 0.001, and p < 0.05) and with the duration (p < 0.01, p < 0.05, and p < 0.01) of continuous parenteral hydromorphone A possible mechanism for these findings is hydromorphone-3-glucoronide, a metabolic product of hydromorphone, which has been implicated in neuroexcitatory symptoms in laboratory investigations.